On June 2, 2025, Antonia, Enzo, and colleagues published a study in the British Journal of Pharmacology titled ‘A GLP-1R/Y1 receptor/Y2 receptor triple agonist decreases fentanyl-evoked dopamine release in the nucleus accumbens and attenuates fentanyl taking and seeking in rats’. … Read More
On July 10th, researchers from the Jerlhag and Schmidt laboratories published groundbreaking findings in European Neuropsychopharmacology demonstrating that semaglutide—a GLP-1R medication currently used for diabetes and weight management—significantly reduces cocaine-seeking behaviors in laboratory studies. The study, titled “Semaglutide suppresses cocaine … Read More
Austin Pothikamjorn has officially graduated from the University of Pennsylvania and is leaving the Schmidt Lab to begin an exciting new chapter. He will be joining the Division of Addiction Psychiatry at Beth Israel Deaconess Medical Center in Boston, MA … Read More
Recent studies show that systemic administration of a glucagon-like peptide-1 receptor (GLP-1R) agonist is sufficient to attenuate cocaine seeking. However, the neural mechanisms mediating these effects and the role of endogenous central GLP-1 signaling in cocaine seeking remain unknown. Here, … Read More
Dr. Schmidt will deliver a talk at the National Academies on Tuesday, September 10th, 2024. The event is part of a one-day public workshop organized by a planning committee from the National Academies of Sciences, Engineering, and Medicine. This workshop … Read More
This summer, the Schmidt Lab was delighted to welcome Lucy Olcott, a member of Syracuse University’s Class of 2025, as a summer intern. During her short time with us, Lucy made significant contributions to several complex behavioral projects, enhancing our … Read More
After five years of working in the Schmidt Lab, Riley Merkel (B.A.) is headed west! Congratulations to Riley on her acceptance to Stanford University School of Medicine for graduate studies! Riley made significant contributions to the field of addiction neuroscience … Read More
“Semaglutide’s story becomes even more complicated in drug addiction. Addictive drugs such as cocaine and opioids are generally thought to “hijack” the brain’s natural reward pathways, says Heath Schmidt, a neuropharmacologist at the University of Pennsylvania. Over time, the brain … Read More
The high rates of relapse associated with current medications used to treat opioid use disorder (OUD) necessitate research that expands our understanding of the neural mechanisms regulating opioid taking to identify molecular substrates that could be targeted by novel pharmacotherapies … Read More
“We’re talking about a class of medications that could have efficacy in treating a variety of addictions: cocaine, opioids, nicotine, alcohol, all different addictive drugs with very different pharmacology,” said Heath Schmidt, a neuroscientist studying addiction at the University of … Read More